大阪大学 · 医学
Imamura教授の研究室は、腎臓移植に伴う虚血再灌流障害に注目し、細胞死の制御や酸化的損傷の軽減を目的とした新規治療戦略の開発を進めています。特にp53の一時的阻害や、カルバミル化エリスロポエチン（CEPO）、水素放出ナノシリコンといった新規分子・ナノ材料の応用を柱としています。腎機能の保護と移植後の長期予後改善を目的とした翻訳的研究を実施しており、臨床応用に向けた基盤を強化しています。
Figures are computed from collected data and may differ slightly.
Renal ischemia-reperfusion (I/R) injury, which is unavoidable in renal transplantation, frequently influences both short- and long-term allograft survival. Despite decades of laboratory and clinical investigations, and the advent of renal replacement therapy, the overall mortality rate due to acute tubular injury has changed little. I/R-induced DNA damage results in p53 activation in proximal tubule cells (PTC), leading to their apoptosis. Therefore, we examined the therapeutic effect of tempora
Several studies have shown that erythropoietin (EPO) can protect the kidneys from ischemia-reperfusion injury and can raise the hemoglobin (Hb) concentration. Recently, the EPO molecule modified by carbamylation (CEPO) has been identified and was demonstrated to be able to protect several organs without increasing the Hb concentration. We hypothesized that treatment with CEPO would protect the kidneys, partly due to the increased peritubular capillaries. The therapeutic effect of CEPO was evalua
Organ ischemia-reperfusion injury (IRI), which is unavoidable in kidney transplantation, induces the formation of reactive oxygen species and causes organ damage. Although the efficacy of molecular hydrogen (H<sub>2</sub>) in IRI has been reported, oral intake of H<sub>2</sub>-rich water and inhalation of H<sub>2</sub> gas are still not widely used in clinical settings because of the lack of efficiency and difficulty in handling. We successfully generated large quantities of H<sub>2</sub> molecu
Kidney transplantation is the most promising treatment to improve mortality and life quality in end-stage kidney disease; however, cancer remains a leading cause of death. Several factors including immunosuppressants might be associated with a gradual increase in cumulative cancer incidence after kidney transplantation. Risk factors for cancer and overall and cancer-specific survival were analyzed in 1973 kidney transplant recipients from three study institutions in Japan. The 5-, 10-, 20-, and
Japan Society for the Promotion of Science (JSPS, grant number 17H04188), Japan Agency of Medical Research and Development (AMED, JP20gm5010001), Osaka Kidney Bank (OKF19-0010), Shiseido Co., Ltd and KAGAMI Inc.
Open papers in the app to read, cite, and organize with AI.
